JPH04344464A - Fluorescent labeling pigment, biogenic material labeled by fluorescent labeling pigment and reagent coating them - Google Patents
Fluorescent labeling pigment, biogenic material labeled by fluorescent labeling pigment and reagent coating themInfo
- Publication number
- JPH04344464A JPH04344464A JP11716791A JP11716791A JPH04344464A JP H04344464 A JPH04344464 A JP H04344464A JP 11716791 A JP11716791 A JP 11716791A JP 11716791 A JP11716791 A JP 11716791A JP H04344464 A JPH04344464 A JP H04344464A
- Authority
- JP
- Japan
- Prior art keywords
- group
- fluorescent labeling
- ring
- reagent
- chemical formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 26
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 18
- 238000001215 fluorescent labelling Methods 0.000 title claims abstract description 18
- 239000000049 pigment Substances 0.000 title abstract description 9
- 239000000463 material Substances 0.000 title abstract 3
- 230000000035 biogenic effect Effects 0.000 title abstract 2
- 239000011248 coating agent Substances 0.000 title 1
- 238000000576 coating method Methods 0.000 title 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000427 antigen Substances 0.000 claims abstract description 13
- 102000036639 antigens Human genes 0.000 claims abstract description 13
- 108091007433 antigens Proteins 0.000 claims abstract description 13
- 125000003118 aryl group Chemical group 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 125000005843 halogen group Chemical group 0.000 claims abstract description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims description 40
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 239000000975 dye Substances 0.000 claims description 12
- 125000005647 linker group Chemical group 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 229910052718 tin Inorganic materials 0.000 claims description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 3
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 claims description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 3
- OTXOHOIOFJSIFX-POYBYMJQSA-N [[(2s,5r)-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)O)CC[C@@H]1N1C(=O)NC(=O)C=C1 OTXOHOIOFJSIFX-POYBYMJQSA-N 0.000 claims description 3
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 claims description 3
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 229910052793 cadmium Inorganic materials 0.000 claims description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 3
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 claims description 3
- 229910052733 gallium Inorganic materials 0.000 claims description 3
- 229910052732 germanium Inorganic materials 0.000 claims description 3
- 125000004437 phosphorous atom Chemical group 0.000 claims description 3
- 108091033319 polynucleotide Proteins 0.000 claims description 3
- 239000002157 polynucleotide Substances 0.000 claims description 3
- 102000040430 polynucleotide Human genes 0.000 claims description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 claims description 2
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 230000010355 oscillation Effects 0.000 abstract description 5
- 239000004065 semiconductor Substances 0.000 abstract description 5
- 238000005259 measurement Methods 0.000 abstract description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 229930192474 thiophene Natural products 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 28
- -1 chlorine-substituted copper Chemical class 0.000 description 27
- 239000011701 zinc Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 6
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000011135 tin Substances 0.000 description 4
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 2
- KMHSUNDEGHRBNV-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carbonitrile Chemical compound ClC1=NC=C(C#N)C(Cl)=N1 KMHSUNDEGHRBNV-UHFFFAOYSA-N 0.000 description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- XQXPVVBIMDBYFF-UHFFFAOYSA-N 4-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C=C1 XQXPVVBIMDBYFF-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- RBTKNAXYKSUFRK-UHFFFAOYSA-N heliogen blue Chemical compound [Cu].[N-]1C2=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=NC([N-]1)=C(C=CC=C3)C3=C1N=C([N-]1)C3=CC=CC=C3C1=N2 RBTKNAXYKSUFRK-UHFFFAOYSA-N 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- PCDQPRRSZKQHHS-XVFCMESISA-N CTP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-XVFCMESISA-N 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 1
- DQTRYXANLKJLPK-UHFFFAOYSA-N chlorophosphonous acid Chemical compound OP(O)Cl DQTRYXANLKJLPK-UHFFFAOYSA-N 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KUHRIIPUCPOQMQ-UHFFFAOYSA-N n,n-diethyl-3-(ethyliminomethylideneamino)propan-1-amine Chemical compound CCN=C=NCCCN(CC)CC KUHRIIPUCPOQMQ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- SCPYDCQAZCOKTP-UHFFFAOYSA-N silanol Chemical compound [SiH3]O SCPYDCQAZCOKTP-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229930004668 tropane alkaloid Natural products 0.000 description 1
- 150000003813 tropane derivatives Chemical class 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
【0001】0001
【産業上の利用分野】本発明は、蛍光標識用色素、蛍光
標識用色素で標識された生物由来物質、及びそれらを含
有する試薬に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to fluorescent labeling dyes, biological substances labeled with fluorescent labeling dyes, and reagents containing them.
【0002】0002
【従来の技術】フタロシアニン系顔料は、環状共役鎖を
構成する4つの窒素原子によって結合された4個のイソ
インドール部分を有する有機顔料である。これらの顔料
に用いられている化合物としては、フタロシアニン(青
緑)、銅フタロシアニン(青)、塩素置換銅フタロシア
ニン(緑)、スルホン化銅フタロシアニン(緑)等があ
る。フタロシアニン系顔料は、一般に、エナメル、プラ
スチック、リノリウム、インク、壁紙、織物、紙、ゴム
製品などに使用されている。いっぽう、フリーベースフ
タロシアニン、アルミニウム、カドミウム、マグネシウ
ム、シリコン、すず及び亜鉛フタロシアニンが螢光を示
すことが報告された(ThePhthalocyani
nes 1:127、1983)。BACKGROUND OF THE INVENTION Phthalocyanine pigments are organic pigments having four isoindole moieties linked by four nitrogen atoms constituting a cyclic conjugated chain. Compounds used in these pigments include phthalocyanine (blue-green), copper phthalocyanine (blue), chlorine-substituted copper phthalocyanine (green), and sulfonated copper phthalocyanine (green). Phthalocyanine pigments are commonly used in enamel, plastics, linoleum, inks, wallpaper, textiles, paper, rubber products, etc. On the other hand, it has been reported that free-based phthalocyanines, aluminum, cadmium, magnesium, silicon, tin and zinc phthalocyanines exhibit fluorescence (The Phthalocyanine).
nes 1:127, 1983).
【0003】また、フタロシアニン類は種々の免疫分析
に使用できることが種々報告されている(US特許第4
,160,645号公報、US特許第4,193,98
3号公報、US特許第4,220,450号公報、US
特許第4,233,402号公報、US特許第4,23
5,869号公報、US特許第4,256,834号公
報、US特許第4,277,437号公報、US特許第
4,318,707号公報、US特許第4,483,9
29号公報、US特許第4,540,660号公報、U
S特許第4,540,670号公報、US特許第4,5
60,534号公報、US特許第4,650,770号
公報、US特許第4,656,129号公報、US特許
第4,659,676号公報)。[0003] It has also been reported that phthalocyanines can be used in various immunoassays (US Pat. No. 4
, 160,645, US Pat. No. 4,193,98
Publication No. 3, US Patent No. 4,220,450, US
Patent No. 4,233,402, US Patent No. 4,23
No. 5,869, US Patent No. 4,256,834, US Patent No. 4,277,437, US Patent No. 4,318,707, US Patent No. 4,483,9
No. 29, US Pat. No. 4,540,660, U.
S Patent No. 4,540,670, US Patent No. 4,5
No. 60,534, US Patent No. 4,650,770, US Patent No. 4,656,129, US Patent No. 4,659,676).
【0004】更に、フタロシアニン類は、化学発光免疫
分析系で触媒として使用されている〔Bull.Che
m.Soc.Jpn.第56巻、2965−2968頁
(1983)、同第56巻、2267−2271頁(1
983)、同第57巻、587−588頁(1984)
、同第57巻、3009−3010頁(1984)、同
第58巻、1299−1303頁(1985)〕。原ら
は、ルミノールと過酸化水素とのあいだの化学発光反応
の触媒として鉄フタロシアニンを用いて、化学発光のシ
グナル量から、テストサンプル中の分析対象を定量して
いる。彼らは鉄及びコバルトのフタロシアニン並びに鉄
、パラジウム、白金、マンガン及びスズのポルフィリン
錯体について検討し、鉄フタロシアニンが最も優れた触
媒作用を示し、かつ高感度であることを報告した。Furthermore, phthalocyanines are used as catalysts in chemiluminescent immunoassay systems [Bull. Che
m. Soc. Jpn. Vol. 56, pp. 2965-2968 (1983), Vol. 56, pp. 2267-2271 (1983)
983), Vol. 57, pp. 587-588 (1984)
, Vol. 57, pp. 3009-3010 (1984), Vol. 58, pp. 1299-1303 (1985)]. Hara et al. use iron phthalocyanine as a catalyst for the chemiluminescent reaction between luminol and hydrogen peroxide, and quantify the analyte in the test sample from the amount of chemiluminescent signal. They investigated iron and cobalt phthalocyanines and porphyrin complexes of iron, palladium, platinum, manganese, and tin, and reported that iron phthalocyanine showed the best catalytic activity and high sensitivity.
【0005】免疫分析で着色物質のほかに螢光物質が広
く利用されているが、さらに、酵素免疫分析においても
、螢光物質は感度を上げることができるので着色物質よ
りも好んで使用されるようになってきている。よく知ら
れた螢光物質−酵素対はアルカリホスファターゼ(al
kaline phosphatase)と4−メチ
ルウムベリフェリルホスフェート(4−methylu
mbelliferylphosphate)、β−ガ
ラクトシダーゼ(β−galactosidase)と
4−メチルウムベリフェリル−D−ガラクトピラノシド
(4−methylumbelliferyl−D−g
alactopyranoside)、西洋ワサビのパ
ーオキシダーゼ(horse radish pe
roxidase)とp−ヒドロキシフェニル酢酸(p
−hydroxyphenyl acetic a
cid)等があり、これらの系の検出感度は10−15
Mである。
しかし検出感度をさらに上げようとしても生成する螢光
体の分析特性には限界がある。Fluorescent substances are widely used in addition to colored substances in immunoassays, and fluorescent substances are also preferred over colored substances in enzyme immunoassays because they can increase sensitivity. It's starting to look like this. A well-known fluorophore-enzyme pair is alkaline phosphatase (al
kaline phosphatase) and 4-methylumbelliferyl phosphate (4-methyl
β-galactosidase and 4-methylumbelliferyl-D-galactopyranoside (4-methylumbelliferyl-D-g
horseradish peroxidase (alactopyranoside), horseradish peroxidase
roxidase) and p-hydroxyphenylacetic acid (p
-hydroxyphenyl acetic a
cid), etc., and the detection sensitivity of these systems is 10-15
It is M. However, even if we try to further increase the detection sensitivity, there are limits to the analytical properties of the produced fluorophore.
【0006】最近、螢光量子収率が高く、水に対して高
い溶解性を示すフタロシアニン類を用いた試薬が提案さ
れた(WO特許第88/04777号公報、WO特許第
90/02747号公報、特開平1−233222号公
報)。[0006]Recently, reagents using phthalocyanines that have a high fluorescence quantum yield and high solubility in water have been proposed (WO Patent No. 88/04777, WO Patent No. 90/02747, JP-A-1-233222).
【0007】[0007]
【発明が解決しようとする課題】しかし、フタロシアニ
ンは吸光係数の特に大きなQ(0,0)吸収帯が665
〜680nmの領域にあって、660nm以下の波長域
では吸収は比較的に小さいので、660nm以下に発振
波長をもつ安価で小型の半導体レーザを用いた測定装置
を使用した場合には、検出薬としての優れた役目を期待
できない。[Problem to be Solved by the Invention] However, phthalocyanine has a Q(0,0) absorption band with a particularly large extinction coefficient of 665.
~680nm, and the absorption is relatively small in the wavelength range of 660nm or less, so when using a measurement device that uses an inexpensive and small semiconductor laser with an oscillation wavelength of 660nm or less, it is difficult to use as a detection drug. I cannot expect a good role from him.
【0008】本発明は、660nm以下の発振波長をも
つ小型で安価な半導体レーザを用いて測定するための、
種々の抗原、薬物の分析やあるいはDNAの塩基配列の
分析等に有用な試薬又は臨床検査試薬を提供することを
目的とする。The present invention provides a method for measuring using a small and inexpensive semiconductor laser having an oscillation wavelength of 660 nm or less.
The purpose of the present invention is to provide reagents or clinical test reagents useful for the analysis of various antigens, drugs, DNA base sequences, etc.
【0009】[0009]
【課題を解決するための手段】本発明は下記(1)〜(
9)に関するものである。すなわち、(1)化2[Means for Solving the Problems] The present invention provides the following (1) to (
9). That is, (1) chemical formula 2
【化2
】
〔化2中、Mは、H2 、Al、Si、P、Ga、Ge
、Cd、Sc、Mg、Sn又はZnを示し、A、B、C
、及びDで示される芳香環は、それぞれ独立にチオフェ
ン環、フラン環、ピロール環、イミダゾール環、チアゾ
ール環、オキサゾール環、イソチアゾール環又はピラゾ
ール環を示し、R1 、R2 、R3 及びR4 は、
それぞれ独立に、−XQW、−QW、−W又は水素原子
を示し、Xは、酸素原子、窒素原子、イオウ原子、リン
原子、ケイ素原子、セレン原子、CR5 R6 (ただ
し、R5 及びR6 は、それぞれ独立に、水素原子、
アルキル基、アリール基又はアラルキル基であり、R5
R6 としてカルボニル酸素でもよい。)、又はフェ
ニレン基を示し、Qは、XとWの結合基(リンカー)を
示し、Wは−OH、−O− 、−SH、−S− 、−C
O2 H、−CO2 − 、−OCH2 CO2 H、
−OCH2 CO2 − 、−PO42 − 、−PO
3− 、−SO3−、 −SO2− 、−SO2 C
l、−SO4 2 − 、−NH2 、−NHR7 、
−NR8 R9 又は−N(+)R10R11R
12(ただし、R7 〜R12は、それぞれ独立に
C1 〜C10のアルキル基、C6 〜C12のア
リール基又はC6 〜C12のアラル キル基で
ある。)であり、k、l、m及びnは、それぞれ独立に
0〜4の整数を示し、Yは、ハロゲン原子、−OR13
又は−NR142 (ただし、R13及びR14は、そ
れぞれ独立に、水素原子、親水性置換基を有するもので
あってもよいアルキル基、親水性置換基を有するもので
あってもよいアシル基、親水性置換基を有するものであ
ってもよいシリル基又は親水性置換基を有するものであ
ってもよいリン原子含有基である。)を示し、pは、Y
のMへの結合数を表わす0〜2の整数を示す。〕で表さ
れる蛍光標識用色素。
(2)上記(1)の蛍光標識用色素を含有する試薬。
(3)上記(1)の蛍光標識用色素で標識された生物由
来物質。
(4)上記(3)の標識された生物由来物質を含有する
試薬。
(5)生物由来物質が抗原、抗体又はヌクレオチドであ
る上記(3)又は(4)の試薬。
(6)抗原が薬物である上記(5)の試薬。
(7)抗体がモノクローナル抗体である上記(5)の試
薬。
(8)ヌクレオチドがオリゴヌクレオチド又はポリヌク
レオチドである上記(5)の試薬。
(9)ヌクレオチドがATP、CTP、GTP、TTP
、UTP、dATP、dCTP、dGTP、dTTP、
dUTP、ddATP、ddCTP、ddGTP、dd
TTP、ddUTP又はこれらの誘導体である上記(5
)の試薬。[chemical 2
] [In chemical formula 2, M is H2, Al, Si, P, Ga, Ge
, Cd, Sc, Mg, Sn or Zn, A, B, C
The aromatic rings represented by , and D each independently represent a thiophene ring, a furan ring, a pyrrole ring, an imidazole ring, a thiazole ring, an oxazole ring, an isothiazole ring, or a pyrazole ring, and R1 , R2 , R3 and R4 are
Each independently represents -XQW, -QW, -W or a hydrogen atom; independently, a hydrogen atom,
It is an alkyl group, an aryl group or an aralkyl group, and R5
Carbonyl oxygen may be used as R6. ), or a phenylene group, Q represents a bonding group (linker) between X and W, and W represents -OH, -O-, -SH, -S-, -C
O2 H, -CO2 -, -OCH2 CO2 H,
-OCH2 CO2 - , -PO42 - , -PO
3-, -SO3-, -SO2-, -SO2C
l, -SO4 2 -, -NH2, -NHR7,
-NR8 R9 or -N(+)R10R11R
12 (However, R7 to R12 are each independently
They are a C1 to C10 alkyl group, a C6 to C12 aryl group, or a C6 to C12 aralkyl group. ), k, l, m and n each independently represent an integer of 0 to 4, Y is a halogen atom, -OR13
or -NR142 (However, R13 and R14 each independently represent a hydrogen atom, an alkyl group that may have a hydrophilic substituent, an acyl group that may have a hydrophilic substituent, a hydrophilic is a silyl group that may have a substituent or a phosphorus atom-containing group that may have a hydrophilic substituent), and p is Y
An integer from 0 to 2 representing the number of bonds to M. ] Fluorescent labeling dye. (2) A reagent containing the fluorescent labeling dye of (1) above. (3) A biological substance labeled with the fluorescent labeling dye of (1) above. (4) A reagent containing the labeled biological substance of (3) above. (5) The reagent according to (3) or (4) above, wherein the biological substance is an antigen, antibody, or nucleotide. (6) The reagent according to (5) above, wherein the antigen is a drug. (7) The reagent according to (5) above, wherein the antibody is a monoclonal antibody. (8) The reagent according to (5) above, wherein the nucleotide is an oligonucleotide or a polynucleotide. (9) Nucleotides are ATP, CTP, GTP, TTP
, UTP, dATP, dCTP, dGTP, dTTP,
dUTP, ddATP, ddCTP, ddGTP, dd
The above (5) which is TTP, ddUTP or a derivative thereof
) reagent.
【0010】本発明の化2の化合物において、R1〜R
4のX中のR5 及びR6 のアルキル基の具体例とし
ては、メチル基、エチル基、プロピル基、sec−プロ
ピル基、n−ブチル基、iso−ブチル基、t−ブチル
基、ペンチル基、ヘキシル基等があり、アリール基の例
としては、フェニル基、チエニル基、フリル基、ピロリ
ル基、トリル基、アニシル基、4−アミノフェニル基等
があり、アラルキル基としては、ベンジル基、2−フェ
ニルエチル基、1−フェニルエチル基、3−フェニルプ
ロピル基、2−フェニルプロピル基、1−フェニルプロ
ピル基等がある。また、Y中のR13及びR14の親水
性置換基を有するものであってもよいアルキル基の具体
例としては、メチル基、エチル基、プロピル基、ブチル
基、ペンチル基、ヘキシル基、ヘプチル基、オクチル基
、ノニル基、デシル基、ドデシル基、テトラデシル基、
ヘキサデシル基、オクタデシル基、エイコシル基、ドコ
シル基等の直鎖、分枝及び脂環状の基があり、親水性置
換基を有するものであってもよいアシル基の例としては
、ホルミル基、アセチル基、プロピオニル基、ブチリル
基、バレリル基、ピバロイル基、ヘキサノイル基、オク
タノイル基、ラウリル基、パルミチル基、ステアリル基
等があり、親水性置換基を有するものであってもよいシ
リル基としては、トリメチルシリル基、トリエチルシリ
ル基、トリプロピルシリル基、トリブチルシリル基、ト
リアミルシリル基、トリヘキシルシリル基、t−ブチル
ジメチルシリル基、ジ(t−ブチル)メチルシリル基、
ジメチルフェニルシリル基、ジフェニルメチルシリル基
、トリフェニルシリル基等がある。In the compound of formula 2 of the present invention, R1 to R
Specific examples of the alkyl groups for R5 and R6 in Examples of aryl groups include phenyl group, thienyl group, furyl group, pyrrolyl group, tolyl group, anisyl group, 4-aminophenyl group, and examples of aralkyl groups include benzyl group, 2-phenyl group, etc. Examples include ethyl group, 1-phenylethyl group, 3-phenylpropyl group, 2-phenylpropyl group, and 1-phenylpropyl group. Further, specific examples of the alkyl group which may have a hydrophilic substituent for R13 and R14 in Y include methyl group, ethyl group, propyl group, butyl group, pentyl group, hexyl group, heptyl group, Octyl group, nonyl group, decyl group, dodecyl group, tetradecyl group,
There are linear, branched, and alicyclic groups such as hexadecyl, octadecyl, eicosyl, and docosyl groups, and examples of acyl groups that may have hydrophilic substituents include formyl and acetyl groups. , propionyl group, butyryl group, valeryl group, pivaloyl group, hexanoyl group, octanoyl group, lauryl group, palmityl group, stearyl group, etc. Silyl groups that may have hydrophilic substituents include trimethylsilyl group , triethylsilyl group, tripropylsilyl group, tributylsilyl group, triamylsilyl group, trihexylsilyl group, t-butyldimethylsilyl group, di(t-butyl)methylsilyl group,
Examples include dimethylphenylsilyl group, diphenylmethylsilyl group, and triphenylsilyl group.
【0011】QはXとWを結合する基で、C1〜C8の
飽和又は不飽和の直鎖状、分枝状又は脂環状の結合基、
例えば、メチレン基、エチレン基、トリメチレン基、テ
トラメチレン基、プロピレン基、ビニレン基、プロペニ
レン基、シクロプロピレン基、シクロペンチレン基、シ
クロヘキシレン基等のほか、ポリエーテル、ポリアミン
、ポリアルコール等の基がある。Q is a group that connects X and W, and is a C1 to C8 saturated or unsaturated linear, branched or alicyclic bonding group;
For example, in addition to methylene group, ethylene group, trimethylene group, tetramethylene group, propylene group, vinylene group, propenylene group, cyclopropylene group, cyclopentylene group, cyclohexylene group, etc., groups such as polyether, polyamine, polyalcohol, etc. There is.
【0012】W中、R7 〜R12のC1〜C10のア
ルキル基としては、メチル基、エチル基、プロピル基、
ブチル基、アミル基、ヘキシル基、ヘプチル基、ノニル
基、デシル基の直鎖状、分枝状及び環状の基があり、C
6〜C12のアリール基としては、フェニル基、トリル
基、アニシル基、ナフチル基、ビフェニル基等があり、
C6〜C12のアラルキル基としては、ベンジル基、2
−フェニルエチル基、1−フェニルエチル基、3−フェ
ニルプロピル基、2−フェニルプロピル基、1−フェニ
ルプロピル基等がある。In W, the C1 to C10 alkyl groups of R7 to R12 include methyl group, ethyl group, propyl group,
There are linear, branched, and cyclic groups such as butyl group, amyl group, hexyl group, heptyl group, nonyl group, and decyl group, and C
Examples of the 6-C12 aryl group include phenyl group, tolyl group, anisyl group, naphthyl group, biphenyl group, etc.
C6 to C12 aralkyl groups include benzyl group, 2
-phenylethyl group, 1-phenylethyl group, 3-phenylpropyl group, 2-phenylpropyl group, 1-phenylpropyl group, etc.
【0013】また、R13及びR14で表されるリン原
子を含む置換基としては、
−P(=O)R15R16, −P(=O)(NR1
7R18)2 , −PR192
(R15〜R19は、それぞれ独立に、アルキル基、ア
リール基、アシル基、シクロアルキル基、アルコキシル
基、アリールオキシル基、ポリエーテル基、ヒドロキシ
ル基又はハロゲン原子を示し、それらは種々の置換基を
持っていてもよい。)がある。In addition, the substituents containing a phosphorus atom represented by R13 and R14 include -P(=O)R15R16, -P(=O)(NR1
7R18)2, -PR192 (R15 to R19 each independently represent an alkyl group, an aryl group, an acyl group, a cycloalkyl group, an alkoxyl group, an aryloxyl group, a polyether group, a hydroxyl group, or a halogen atom; ) may have various substituents.
【0014】化2中、Yが−OR13又は−NR142
(R13及びR14は、アルキル基、アシル基及びシリ
ル基を示す)であり、pが1又は2を表わす化合物は、
化2中、Yが−OH又は−NH2 である化合物を、相
当するアルコール、アシルクロリド、シラノール、クロ
ロシラン、クロロホスフィン、クロロホスファイト又は
ホスフォリルクロリドなどと反応させることによって合
成できる。
化2中、Yが−OH又は−NH2 であり、pが1又は
2である化合物は、化2中、Yがハロゲン原子であり、
pが1又は2で表される化合物を加水分解又は加アンモ
ニア分解することによって得ることができる。化2中、
Yがハロゲン原子であり、pが1又は2で表される化合
物、及びpがゼロでYをもたない化合物は、次の2つの
経路により合成することができる。In formula 2, Y is -OR13 or -NR142
(R13 and R14 represent an alkyl group, an acyl group, and a silyl group), and the compound in which p represents 1 or 2 is:
A compound in which Y is -OH or -NH2 in Chemical Formula 2 can be synthesized by reacting with a corresponding alcohol, acyl chloride, silanol, chlorosilane, chlorophosphine, chlorophosphite, phosphoryl chloride, or the like. The compound in which Y is -OH or -NH2 and p is 1 or 2 in Chemical Formula 2, Y is a halogen atom in Chemical Formula 2,
It can be obtained by hydrolyzing or ammonolyzing a compound in which p is 1 or 2. During 2nd year,
Compounds in which Y is a halogen atom and p is 1 or 2, and compounds in which p is zero and do not have Y can be synthesized by the following two routes.
【0015】第1の経路は文献(J. Chem. S
oc. 911頁(1937年))記載の方法を参考に
して、化3The first route is described in the literature (J. Chem.
oc. Referring to the method described on page 911 (1937), chemical formula 3
【化3】
(式中、MはH2 、Al、Si、P、Ga、Ge、C
d、Sc、Mg、Sn又はZnを示し、Yはハロゲン原
子を示し、pはYのMへの結合数を表わす0〜2の整数
を示し、A、B、C、及びDで示される芳香環は、それ
ぞれ独立にチオフェン環、フラン環、ピロール環、イミ
ダゾール環、チアゾール環、オキサゾール環、イソチア
ゾール環又はピラゾール環を示す。)で表される化合物
を得、次にこれに、化2において、置換基R1 、R2
、R3 又はR4 を形成しうるR1 、R2、R3
又はR4 部位を有する化学種を反応させることによ
り化2で表される化合物を得る方法である。[Formula 3] (wherein, M is H2, Al, Si, P, Ga, Ge, C
d, Sc, Mg, Sn or Zn, Y represents a halogen atom, p represents an integer of 0 to 2 representing the number of bonds of Y to M, and aromatic represented by A, B, C, and D. The rings each independently represent a thiophene ring, a furan ring, a pyrrole ring, an imidazole ring, a thiazole ring, an oxazole ring, an isothiazole ring, or a pyrazole ring. ) is obtained, and then, in chemical formula 2, substituents R1 and R2 are added to this compound.
, R2, R3 which can form R3 or R4
Alternatively, the compound represented by the formula 2 is obtained by reacting a chemical species having an R4 site.
【0016】第2の経路は、化4The second route is chemical compound 4
【化4】 又は化5[C4] Or 5
【化5】
(化4及び化5中、Aで示される芳香環は、それぞれ独
立にチオフェン環、フラン環、ピロール環、イミダゾー
ル環、チアゾール環、オキサゾール環、イソチアゾール
環又はピラゾール環を示し、R1 及びkは、化2中と
同じ意味)で表される化合物を、相当する金属又は金属
塩と反応させることによって得ることができる。いっぽ
う、化2中、MがH2 の場合は、化4及び化5で表さ
れる化合物をNa又はLiアルコキシドと反応させ、次
いで加水分解することにより得ることができる。化5で
表される化合物は、化4で表される化合物をメタノール
中、ナトリウムメトキシド存在下アンモニアと反応させ
ることによって得ることができる。embedded image (In Chemical Formulas 4 and 5, the aromatic rings represented by A each independently represent a thiophene ring, a furan ring, a pyrrole ring, an imidazole ring, a thiazole ring, an oxazole ring, an isothiazole ring, or a pyrazole ring, R1 and k have the same meanings as in Chemical Formula 2) can be obtained by reacting a compound represented by the formula (R1 and k have the same meanings as in Chemical Formula 2) with a corresponding metal or metal salt. On the other hand, when M in Chemical Formula 2 is H2, it can be obtained by reacting the compounds represented by Chemical Formulas 4 and 5 with Na or Li alkoxide, and then hydrolyzing. The compound represented by Chemical Formula 5 can be obtained by reacting the compound represented by Chemical Formula 4 with ammonia in methanol in the presence of sodium methoxide.
【0017】本発明において用いられる生物由来物質と
しては、動物、植物、微生物(ウイルスを含む)等の生
物から得られるタンパク質・ペプチド、ヌクレオチド、
糖類、脂質、ホルモン、ビタミン、アルカロイド、抗生
物質、それらの複合物等があり、これらは、天然から抽
出したもの、人工的に完全合成したもの、あるい人工的
に半合成したもののいずれであってもよい。タンパク質
・ペプチドの具体例としては、血清アルブミン、IgG
・IgA・IgM・IgD・IgE等の免疫グロブリン
、種々のタンパク質や白血球の膜抗原に対するモノクロ
ーナル抗体、パーオキシダーゼ、グルコースオキシダー
ゼ、アルカリホスファターゼ等の酵素等が挙げられ、ヌ
クレオチドの具体例としてはDNA、RNA、合成オリ
ゴヌクレオチド、合成ポリヌクレオチド、ATP、CT
P、GTP、TTP、UTP、dATP、dCTP、d
GTP、dTTP、dUTP、ddATP、ddCTP
、ddGTP、ddTTP、ddUTP、あるいはそれ
らの誘導体等が挙げられ、糖類の具体例としては、グリ
コーゲン、デンプン、マンナン等の多糖類のほかオリゴ
糖やグルコース、マンノース等の単糖類が挙げられ、脂
質としては、ホスファチジルコリン、ホスファチジルエ
タノラミン、脂肪、脂肪酸等が挙げられ、ホルモンとし
てはインシュリン、成長ホルモン、オキシトシン、バソ
プレッシン、セクレチン、上皮細胞成長因子、ガストリ
ン、グルカゴン、カルシトニン等のペプチド性ホルモン
、アンドロゲン、エストロゲン、ハイドロコーチゾン等
のステロイドホルモン、アドレナリン、ノルアドレナリ
ン等のカテコラミン類等が挙げられ、ビタミンとしては
ビタミンA、ビタミンB1、B2、B6、B12、ビオ
チン、葉酸、ビタミンC、ビタミンD、ビタミンE等の
各種ビタミンが挙げられ、アルカロイドとしてはモルフ
ィン等のアヘンアルカロイド、アトロピン、スコポラミ
ン等のトロパンアルカロイド、ビンブラスチン、ビンク
リスチン等のインドールアルカロイド、オウレン等のイ
ソキノリンアルカロイド等が挙げられ、抗生物質として
は、ペニシリン、セファロスポリン、カナマイシン、エ
リスロマイシン、クロラムフェニコール等が挙げられる
。[0017] The biological substances used in the present invention include proteins, peptides, nucleotides, etc. obtained from living organisms such as animals, plants, and microorganisms (including viruses).
There are sugars, lipids, hormones, vitamins, alkaloids, antibiotics, and complexes thereof, and these may be extracted from nature, completely synthetically synthesized, or semi-synthesized artificially. You can. Specific examples of proteins/peptides include serum albumin, IgG
- Immunoglobulins such as IgA, IgM, IgD, and IgE, monoclonal antibodies against various proteins and leukocyte membrane antigens, enzymes such as peroxidase, glucose oxidase, and alkaline phosphatase, etc., and specific examples of nucleotides include DNA and RNA. , synthetic oligonucleotide, synthetic polynucleotide, ATP, CT
P, GTP, TTP, UTP, dATP, dCTP, d
GTP, dTTP, dUTP, ddATP, ddCTP
, ddGTP, ddTTP, ddUTP, or derivatives thereof. Specific examples of saccharides include polysaccharides such as glycogen, starch, and mannan, as well as monosaccharides such as oligosaccharides, glucose, and mannose; Examples include phosphatidylcholine, phosphatidylethanolamine, fats, fatty acids, etc. Hormones include insulin, growth hormone, oxytocin, vasopressin, secretin, epidermal growth factor, gastrin, glucagon, peptide hormones such as calcitonin, androgens, estrogens, Examples include steroid hormones such as hydrocortisone, catecholamines such as adrenaline and noradrenaline, and various vitamins such as vitamin A, vitamin B1, B2, B6, B12, biotin, folic acid, vitamin C, vitamin D, and vitamin E. Examples of alkaloids include opium alkaloids such as morphine, tropane alkaloids such as atropine and scopolamine, indole alkaloids such as vinblastine and vincristine, and isoquinoline alkaloids such as ouren. Examples of antibiotics include penicillin, cephalosporin, Examples include kanamycin, erythromycin, chloramphenicol, and the like.
【0018】生物由来物質に蛍光標識用色素を結合させ
るためには、生物由来物質中のアミノ基、水酸基等の官
能基と蛍光標識用色素中のカルボキシル基、スルフォン
基等の官能基を利用して直接、イオン結合的又は共有結
合的に直接結合させるか、あるいは蛍光標識用色素が反
応できるように、生物由来物質の一部に結合基(リンカ
ー)を付加する等の化学修飾を施したのち、反応させれ
ばよい。蛍光標識用色素で標識された生物由来物質はク
ロマトグラフィー、再結晶等の慣用の分離手段により精
製することができる。[0018] In order to bond a fluorescent labeling dye to a biological substance, the functional groups such as amino groups and hydroxyl groups in the biological substance and the carboxyl group and sulfone group in the fluorescent labeling dye are used. directly, ionic or covalently bonded, or after chemical modification such as adding a binding group (linker) to a part of the biological material so that the fluorescent labeling dye can react with it. , just react. A biological substance labeled with a fluorescent labeling dye can be purified by conventional separation means such as chromatography and recrystallization.
【0019】化2で表される化合物は、フタロシアニン
に比べて短波長域(660nm以下)にQ(0,0)帯
に基づく大きな吸収極大を有することから、660nm
に発振波長をもつ安価で小型の半導体レーザを用いて測
定するための、種々の抗原、薬物の分析やあるいはDN
Aの塩基配列の分析等に有用な、精度の高い試薬又は臨
床検査試薬として利用できる。The compound represented by chemical formula 2 has a large absorption maximum based on the Q(0,0) band in a short wavelength region (660 nm or less) compared to phthalocyanine, so it has a large absorption maximum at 660 nm.
Analysis of various antigens, drugs, or DN
It can be used as a highly accurate reagent useful for analysis of the base sequence of A or as a clinical test reagent.
【0020】[0020]
【実施例】以下、実施例により更に具体的に本発明を説
明する。
実施例 1
(1)化2中、MがZn、R1〜R4がいずれもヒドロ
キシカルボニル基、A、B、C及びDがいずれもチオフ
ェン環、k、l、m及びnがいずれも1、かつpが0で
Yのない化合物の合成
文献〔J. Chem. Soc., 911頁(19
37年)〕記載の方法を参考にして、化2中、MがZn
、R1〜R4がいずれもヒドロキシカルボニル基、A、
B、C及びDがいずれもチオフェン環、k、l、m及び
nがいずれも1、かつpが0でYのない化合物を合成し
た。EXAMPLES The present invention will now be explained in more detail with reference to Examples. Example 1 (1) In chemical formula 2, M is Zn, R1 to R4 are all hydroxycarbonyl groups, A, B, C and D are all thiophene rings, k, l, m and n are all 1, and Synthesis literature of compounds with p=0 and no Y [J. Chem. Soc. , 911 pages (19
37)] With reference to the method described, in chemical formula 2, M is Zn.
, R1 to R4 are all hydroxycarbonyl groups, A,
A compound in which B, C, and D are all thiophene rings, k, l, m, and n are all 1, p is 0, and Y is absent was synthesized.
【0021】(2)リンカーが結合したオリゴヌクレオ
チド・プライマーの合成
固相CED−フォスフォラミド法を用いた自動DNA合
成装置によりプライマー(5’−GTTTCCCAGT
CACGAC−3’)を合成した。合成したプライマー
のリン酸化は、50mMトリス−塩酸(pH7.6)、
10mM塩化マグネシウム、10mMジチオスレイトー
ル、3mM ATP、T4−ヌクレオチドカイネースを
含む100μlの反応液中で37℃、1時間保温して行
った。リン酸化されたプライマーは、ゲル濾過用カラム
を使用して高速液体クロマトグラフィー(HPLC)で
分離し、リン酸化されたプライマーのピークを集め、凍
結乾燥で溶媒を除いた。次に、これを250mMの1,
2−ジアミノエタン(pH6.0),200mMのエチ
ル−3(3−ジエチルアミノプロピル)カルボジイミド
及び100mMのN−メチルイミダゾール(pH6.0
)を含む反応液100μl中、25℃で一晩保温して5
’末端のグアノシンのリン酸部にリンカー〔NH2−(
CH2)2−NH−〕を結合させた。(2) Synthesis of linker-bound oligonucleotide primer The primer (5'-GTTTCCCAGT
CACGAC-3') was synthesized. Phosphorylation of the synthesized primers was carried out using 50mM Tris-HCl (pH 7.6),
The reaction was carried out in a 100 μl reaction solution containing 10 mM magnesium chloride, 10 mM dithiothreitol, 3 mM ATP, and T4-nucleotide kinase at 37° C. for 1 hour. The phosphorylated primer was separated by high performance liquid chromatography (HPLC) using a gel filtration column, the peak of the phosphorylated primer was collected, and the solvent was removed by lyophilization. Next, this was mixed with 250mM of 1,
2-diaminoethane (pH 6.0), 200 mM ethyl-3(3-diethylaminopropyl)carbodiimide and 100 mM N-methylimidazole (pH 6.0).
) in 100 μl of a reaction solution containing
' A linker [NH2-(
CH2)2-NH-] was combined.
【0022】(3)化2中、MがZn、R1〜R4がい
ずれもヒドロキシカルボニル基、A、B、C及びDがい
ずれもチオフェン環、k、l、m及びnがいずれも1、
かつpが0でYのない化合物によって標識されたオリゴ
ヌクレオチド・プライマーの合成上記(1)で合成した
化合物と上記(2)で合成した5’末端グアノシンのリ
ン酸部にリンカーが結合したオリゴヌクレオチド・プラ
イマーを、0.2M炭酸ナトリウム緩衝液(pH9.3
)中で混合し、25℃で一晩、暗所に保温したのち、H
PLCで精製することにより、リンカーを介して化2中
、MがZn、R1〜R4がいずれもヒドロキシカルボニ
ル基、A、B、C及びDがいずれもチオフェン環、k、
l、m及びnがいずれも1、かつpが0でYのない化合
物の結合したプライマーを得た。(3) In formula 2, M is Zn, R1 to R4 are all hydroxycarbonyl groups, A, B, C and D are all thiophene rings, k, l, m and n are all 1,
Synthesis of an oligonucleotide primer labeled with a compound with p of 0 and no Y. The compound synthesized in (1) above and the oligonucleotide synthesized in (2) above with a linker attached to the phosphoric acid moiety of the 5'-terminal guanosine. - Primer in 0.2M sodium carbonate buffer (pH 9.3)
) and kept warm at 25°C overnight in a dark place.
By purifying with PLC, in chemical formula 2, M is Zn, R1 to R4 are all hydroxycarbonyl groups, A, B, C and D are all thiophene rings, k,
A primer was obtained in which l, m, and n were all 1, p was 0, and a compound was bound without Y.
【0023】(4)DNAの塩基配列の分析既知の塩基
配列のDNAをサンプルとし、リンカーを介して化2中
、MがZn、R1〜R4がいずれもヒドロキシカルボニ
ル基、A、B、C及びDがいずれもチオフェン環、k、
l、m及びnがいずれも1、更にpが0でYのない化合
物の結合したプライマーを用いて、それぞれ4種の塩基
でサンガー反応を行ったのち、それぞれ別々のレーンで
電気泳動分離し、650nmの発振波長の半導体レーザ
ーを搭載したDNAシークエンサーで分析した。その結
果、DNAの340塩基までを99%の精度で決定でき
た。(4) Analysis of DNA base sequence DNA with a known base sequence is used as a sample, and in the formula 2, M is Zn, R1 to R4 are all hydroxycarbonyl groups, A, B, C, and D is a thiophene ring, k,
Using a primer bound to a compound in which l, m, and n are all 1, p is 0, and there is no Y, a Sanger reaction is performed with each of the four types of bases, and then electrophoretic separation is performed in separate lanes. The analysis was performed using a DNA sequencer equipped with a semiconductor laser with an oscillation wavelength of 650 nm. As a result, up to 340 bases of DNA could be determined with 99% accuracy.
【0024】実施例2
文献〔J. Chem. Soc., 911頁(19
37年)〕記載の方法を参考にして、化2中、MがH2
、R1〜R4がいずれもスルフォン酸基、A、B、C及
びDがいずれもチオフェン環、k、l、m及びnがいず
れも1、更にpが0でYのない化合物を合成した。以下
、実施例1と同様に操作して、リンカーを介してこの化
合物が結合したプライマーを得、これを用いて、既知の
塩基配列のDNAを分析した結果、DNAの380塩基
までを99%の精度で決定できた。Example 2 Reference [J. Chem. Soc. , 911 pages (19
37)] With reference to the method described, in chemical formula 2, M is H2
, R1 to R4 are all sulfonic acid groups, A, B, C, and D are all thiophene rings, k, l, m, and n are all 1, p is 0, and a compound without Y was synthesized. Hereinafter, in the same manner as in Example 1, a primer to which this compound was bound via a linker was obtained, and DNA with a known base sequence was analyzed using this primer. As a result, up to 380 bases of the DNA were 99% The decision was made with precision.
【0025】実施例3
文献〔J. Chem. Soc., 911頁(19
37年)〕記載の方法を参考にして、化2中、MがAl
、R1〜R4がいずれも5−カルボキシプロピオニル基
、A、B、C及びDがいずれもチオフェン環、k、l、
m及びnがいずれも1、更にpが0でYのない化合物を
合成した。以下、実施例1と同様に操作して、リンカー
を介してこの化合物が結合したプライマーを得、これを
用いて、既知の塩基配列のDNAを分析した結果、DN
Aの280塩基までを99%の精度で決定できた。Example 3 Literature [J. Chem. Soc. , 911 pages (19
37)] With reference to the method described, in chemical formula 2, M is Al.
, R1 to R4 are all 5-carboxypropionyl groups, A, B, C and D are all thiophene rings, k, l,
A compound in which m and n are both 1, p is 0, and Y is absent was synthesized. Hereinafter, in the same manner as in Example 1, a primer to which this compound was bound via a linker was obtained, and DNA with a known base sequence was analyzed using this primer.
Up to 280 bases of A could be determined with 99% accuracy.
【0026】実施例4
文献〔J. Chem. Soc., 911頁(19
37年)〕記載の方法を参考にして、化2中、MがZn
、R1〜R4がいずれも5−カルボキシバレリル基、A
、B、C及びDがいずれもチオール環、k、l、m及び
nがいずれも1、かつpが0でYのない化合物を合成し
た。以下、実施例1と同様に操作して、リンカーを介し
てこの化合物が結合したプライマーを得、これを用いて
、既知の塩基配列のDNAを分析した結果、DNAの3
20塩基までを99%の精度で決定できた。Example 4 Literature [J. Chem. Soc. , 911 pages (19
37)] With reference to the method described, in chemical formula 2, M is Zn.
, R1 to R4 are all 5-carboxyvaleryl groups, A
, B, C, and D are all thiol rings, k, l, m, and n are all 1, p is 0, and a compound without Y was synthesized. Hereinafter, in the same manner as in Example 1, a primer to which this compound was bound via a linker was obtained, and as a result of analyzing DNA with a known base sequence using this primer, 3
Up to 20 bases could be determined with 99% accuracy.
【0027】[0027]
【発明の効果】本発明により、660nm以下の波長域
に発振波長をもつ半導体レーザを用いて測定するための
、種々の抗原、薬物あるいはDNAの塩基配列等の分析
に有用な試薬又は臨床検査試薬を提供できた。Effects of the Invention The present invention provides reagents or clinical test reagents useful for analyzing various antigens, drugs, DNA base sequences, etc., for measurement using a semiconductor laser having an oscillation wavelength in the wavelength range of 660 nm or less. We were able to provide
Claims (9)
、Cd、Sc、Mg、Sn又はZnを示し、A、B、C
、及びDで示される芳香環は、それぞれ独立にチオフェ
ン環、フラン環、ピロール環、イミダゾール環、チアゾ
ール環、オキサゾール環、イソチアゾール環又はピラゾ
ール環を示し、R1 、R2 、R3 及びR4 は、
それぞれ独立に、−XQW、−QW、−W又は水素原子
を示し、Xは、酸素原子、窒素原子、イオウ原子、リン
原子、ケイ素原子、セレン原子、CR5 R6 (ただ
し、R5 及びR6 は、それぞれ独立に、水素原子、
アルキル基、アリール基又はアラルキル基であり、R5
R6 としてカルボニル酸素でもよい。)、又はフェ
ニレン基を示し、Qは、XとWの結合基(リンカー)を
示し、Wは−OH、−O− 、−SH、−S− 、−C
O2 H、−CO2 − 、−OCH2 CO2 H、
−OCH2 CO2 − 、−PO42 − 、−PO
3− 、−SO3−、 −SO2− 、−SO2
Cl、−SO4 2 − 、−NH2 、−NHR7
、−NR8 R9 又は−N(+)R10R1
1R12(ただし、R7 〜R12は、それぞれ独立に
C1 〜C10のアルキル基、C6 〜C12
のアリール基又はC6 〜C12のアラル キル
基である。)であり、k、l、m及びnは、それぞれ独
立に0〜4の整数を示し、Yは、ハロゲン原子、−OR
13又は−NR142 (ただし、R13及びR14は
、それぞれ独立に、水素原子、親水性置換基を有するも
のであってもよいアルキル基、親水性置換基を有するも
のであってもよいアシル基、親水性置換基を有するもの
であってもよいシリル基又は親水性置換基を有するもの
であってもよいリン原子含有基である。)を示し、pは
、YのMへの結合数を表わす0〜2の整数を示す。〕で
表される蛍光標識用色素。Claim 1: Chemical formula 1 [Chemical formula 1] [In chemical formula 1, M is H2, Al, Si, P, Ga, Ge
, Cd, Sc, Mg, Sn or Zn, A, B, C
The aromatic rings represented by , and D each independently represent a thiophene ring, a furan ring, a pyrrole ring, an imidazole ring, a thiazole ring, an oxazole ring, an isothiazole ring, or a pyrazole ring, and R1 , R2 , R3 and R4 are
Each independently represents -XQW, -QW, -W or a hydrogen atom; independently, a hydrogen atom,
It is an alkyl group, an aryl group or an aralkyl group, and R5
Carbonyl oxygen may be used as R6. ), or a phenylene group, Q represents a bonding group (linker) between X and W, W is -OH, -O-, -SH, -S-, -C
O2 H, -CO2 -, -OCH2 CO2 H,
-OCH2 CO2 - , -PO42 - , -PO
3-, -SO3-, -SO2-, -SO2
Cl, -SO4 2 -, -NH2, -NHR7
, -NR8 R9 or -N(+)R10R1
1R12 (However, R7 to R12 are each independently a C1 to C10 alkyl group, a C6 to C12
aryl group or C6 to C12 aralkyl group. ), k, l, m and n each independently represent an integer of 0 to 4, Y is a halogen atom, -OR
13 or -NR142 (However, R13 and R14 each independently represent a hydrogen atom, an alkyl group that may have a hydrophilic substituent, an acyl group that may have a hydrophilic substituent, or a hydrophilic substituent. is a silyl group that may have a hydrophilic substituent or a phosphorus atom-containing group that may have a hydrophilic substituent), and p represents the number of bonds of Y to M. Indicates an integer between ~2. ] Fluorescent labeling dye.
試薬。2. A reagent containing the fluorescent labeling dye according to claim 1.
た生物由来物質。3. A biological substance labeled with the fluorescent labeling dye according to claim 1.
含有する試薬。4. A reagent containing the labeled biological substance according to claim 3.
ドである請求項3又は請求項4記載の試薬。5. The reagent according to claim 3 or 4, wherein the biological substance is an antigen, an antibody, or a nucleotide.
記載の試薬。Claim 7: Claim 5 wherein the antibody is a monoclonal antibody.
Reagents listed.
リヌクレオチドである請求項5記載の試薬。8. The reagent according to claim 5, wherein the nucleotide is an oligonucleotide or a polynucleotide.
TTP、UTP、dATP、dCTP、dGTP、dT
TP、dUTP、ddATP、ddCTP、ddGTP
、ddTTP、ddUTP又はこれらの誘導体である請
求項5記載の試薬。Claim 9: The nucleotide is ATP, CTP, GTP,
TTP, UTP, dATP, dCTP, dGTP, dT
TP, dUTP, ddATP, ddCTP, ddGTP
, ddTTP, ddUTP or a derivative thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11716791A JPH04344464A (en) | 1991-05-22 | 1991-05-22 | Fluorescent labeling pigment, biogenic material labeled by fluorescent labeling pigment and reagent coating them |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11716791A JPH04344464A (en) | 1991-05-22 | 1991-05-22 | Fluorescent labeling pigment, biogenic material labeled by fluorescent labeling pigment and reagent coating them |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH04344464A true JPH04344464A (en) | 1992-12-01 |
Family
ID=14705108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11716791A Pending JPH04344464A (en) | 1991-05-22 | 1991-05-22 | Fluorescent labeling pigment, biogenic material labeled by fluorescent labeling pigment and reagent coating them |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH04344464A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1101113A4 (en) * | 1999-06-09 | 2002-05-08 | Ljl Biosystems Inc | Cell-signaling assays |
-
1991
- 1991-05-22 JP JP11716791A patent/JPH04344464A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1101113A4 (en) * | 1999-06-09 | 2002-05-08 | Ljl Biosystems Inc | Cell-signaling assays |
US8568973B2 (en) | 1999-06-09 | 2013-10-29 | Molecular Devices, Llc | Cell-signaling assays |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4898951A (en) | Compounds used as intermediates in the preparations of non-radioactive biological probes | |
US5198537A (en) | Digoxigenin derivatives and use thereof | |
US6582930B1 (en) | Porphyrin compounds, their conjugates and assay methods based on the use of said conjugates | |
JP2866419B2 (en) | Rare earth cryptate, its production method, its synthetic intermediate and its use as a fluorescent tracer | |
CA2421552A1 (en) | Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses | |
EP0518930A1 (en) | Cyclodextrin compositions and methods for pharmaceutical and industrial applications | |
US5438135A (en) | Water-soluble tetraazaporphins and fluorochrome for labeling | |
EP0597389B1 (en) | Water-soluble tetraazaporphins and fluorochrome for labeling | |
JP4068137B2 (en) | Biotinylated chemiluminescent label, conjugate, assay and assay kit | |
US5736624A (en) | Phosphatase activated crosslinking, conjugating and reducing agents; methods of using such agents; and reagents comprising phosphatase activated crosslinking and conjugating agents | |
JPH07502045A (en) | Novel biotinylation reagent | |
JP4098839B2 (en) | Indocyanine compounds | |
JPH07260790A (en) | Biotin silane compound and bond matrix containing compound thereof | |
JPH05287209A (en) | Fluorescent labelling dye, biogenic substance labelled with the same, and reagent containing them | |
JPH04344464A (en) | Fluorescent labeling pigment, biogenic material labeled by fluorescent labeling pigment and reagent coating them | |
EP0155854B1 (en) | Non-radioactive biological probes | |
JPH04351960A (en) | Fluorescent label-coloring matter, organism-derived material labeled tereby and reagent containing these | |
JPH09262099A (en) | Detection of nucleic acid with phosphate of fluorescein derivative | |
JPH05194942A (en) | Fluorescent marking pigment, biogenous substance marked with fluorescent marking pigment, and reagent containing them | |
JPH04351961A (en) | Fluorescent label-coloring matter, organism-derived material labeled tereby and reagent containing these | |
JPH0540121A (en) | Pigment for fluorescence labeling, organism-derived substance labeled with pigment for fluorescence labeling and reagent containing them | |
JP3008690B2 (en) | Method for measuring ligand or receptor | |
JPH05107188A (en) | Pigment for luorescent labeling, boisubstance labeled by same and reagent containing the pigment and substance | |
JPH04320456A (en) | Pigment for fluorescent labeling, bio substance labeled therewith, and reagent containing the same | |
JPH0540097A (en) | Fluorescent labeling dye, organism derived substance labelled therewith and reagent containing them |